A-Synuclein

Oral ingestion of the environmental toxicant trichlorethylene in
rats induces alterations in the gut microbiome: relevance to
idiopathic Parkinson’s disease

A-Synuclein, Enviromental, Gut Dysbiosis, Gut Microbiota, Gut Permeability / Leaky Gut, Oral Microbiome, Parkinson's Disease, Pre-PD, Probiotics, Prebiotics and Symbiotics /

Microbial alterations within the gut microbiome appear to be a common feature of individuals with Parkinson’sdisease (PD), providing further evidence for the role of the gut-brain axis in PD development. As a major site ofcontact with the environment, questions have emerged surrounding the cause and effect of alterations to the gutmicrobiome by environmental contaminants associated […]

Oral ingestion of the environmental toxicant trichlorethylene in
rats induces alterations in the gut microbiome: relevance to
idiopathic Parkinson’s disease Read More »

Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases

A-Synuclein, Autonmic nervous system, Biomarkers, Gut-Brain axis /

Neurodegenerative diseases are hitherto classified based on their core clinical features, the anatomical distribution of neurodegeneration, and the cell populations mainly affected. On the other hand, the wealth of neuropathological, genetic, molecular and biochemical studies have identified the existence of distinct insoluble protein aggregates in the affected brain regions. These findings have spread the use of a

Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases Read More »

α-Synuclein in Parkinson’s disease and advances in detection

A-Synuclein, Biomarkers, Parkinson's Disease, Pre-PD /

Parkinson’s disease (PD) is a threatening neurodegenerative disorder that seriously affects patients’ life quality. Substantial evidence links the overexpression and abnormal aggregation of alpha-synuclein (α-Syn) to PD. α-Syn has been identified as a characteristic biomarker of PD, which indicates its great value of diagnosis and designing effective therapeutic strategy. This article systematically summarizes the pathogenic

α-Synuclein in Parkinson’s disease and advances in detection Read More »

Increased Transferrin Sialylation Predicts Phenoconversion in
Isolated REM Sleep Behavior Disorder

A-Synuclein, Gut Dysbiosis, iRBD /

Sialic acid–protein interactions are involved in regulating central nervous systemimmunity; therefore, derangements in sialylation could beinvolved in neurodegeneration. Decreased serum CDTadj is associatedwith substantia nigra degeneration in synucleinopathies.iRBD patients with low CDTadj are more likely tophenoconvert to manifest disease. CLICK TO REVIEW

Increased Transferrin Sialylation Predicts Phenoconversion in
Isolated REM Sleep Behavior Disorder Read More »

Lactobacillus plantarum DP189 Reduces α-SYN Aggravation in MPTP-Induced Parkinson’s Disease Mice via Regulating Oxidative Damage, Inflammation, and Gut Microbiota Disorder

A-Synuclein, Probiotics, Prebiotics and Symbiotics /

This study aimed to evaluate the attenuating effect of Lactobacillus plantarum DP189 on α-synuclein (α-SYN) aggregates in the substantia nigra (SN) of Parkinson’s disease (PD) mice via 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced. Our results indicated that L. plantarum DP189 increased the levels of superoxide dismutase (SOD), glutathione peroxide (GSH-Px), and interleukin-10 (IL-10) and decreased the levels of malondialdehyde (MDA), reactive oxygen species

Lactobacillus plantarum DP189 Reduces α-SYN Aggravation in MPTP-Induced Parkinson’s Disease Mice via Regulating Oxidative Damage, Inflammation, and Gut Microbiota Disorder Read More »

Biomarkers for REM sleep behavior disorder in idiopathic
and narcoleptic patients

A-Synuclein, iRBD /

To search for discriminating biomarkers, 30 patients with idiopathic rapid-eyemovements sleep behavior disorder (iRBD) were compared with 17 patientswith RBD within narcolepsy type 1. Both groups underwent extensive examinations, including skin biopsy searching for phosphorylated a-synuclein depositsand whole-night video-polysomnography. Skin biopsy was positive for phosphorylated a-synuclein deposits in 86.7% of iRBD patients and in none

Biomarkers for REM sleep behavior disorder in idiopathic
and narcoleptic patients Read More »

Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson’s Disease Using Gait Parameters

A-Synuclein, iRBD, Parkinson's Disease, Pre-PD /

Gait parameters and a pretrained statistical model can robustly distinguish participants with iRBD from HCs and patients with PD. This could be used to screen subjects with future synucleinopathies in the general population and to identify a conversion threshold to PD. CLICK TO REVIEW

Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson’s Disease Using Gait Parameters Read More »

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson’s Disease

A-Synuclein, Dementia - Lewy Bodies, Parkinson's Disease /

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and the fastest growing neurologic disease in the world, yet no disease-modifying therapy is available for this disabling condition. Multiple lines of evidence implicate the protein α-synuclein (α-Syn) in the pathogenesis of PD, and as such, there is intense interest in targeting α-Syn for potential disease modification. α-Syn

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson’s Disease Read More »

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease

A-Synuclein, Autonmic nervous system, Constipation, ENS, Gut Dysbiosis, iRBD, Non-Motor Symptoms, Orthostatic Hypotension, Parkinson's Disease, Pre-PD /

Braak’s hypothesis has been extremely influential over the last two decades. However, neuropathological and clinical evidence suggest that the model does not conform to all patients with Parkinson’s disease (PD). To resolve this controversy, a new model was recently proposed; in brain-first PD, the initial α-synuclein pathology arise inside the central nervous system, likely rostral to

Clinical and imaging evidence of brain-first and body-first Parkinson’s disease Read More »

Environmental triggers of Parkinson’s disease – Implications of the Braak and dual-hit hypotheses

A-Synuclein, Biomarkers, Gut Dysbiosis, Gut Permeability / Leaky Gut, Gut-Brain axis, Olfactory, Parkinson's Disease, Pre-PD /

Idiopathic Parkinson’s disease (PD) may take decades to develop, during which many risk or protective factors may come into play to initiate the pathogenesis or modify its progression to clinical PD. The lack of understanding of this prodromal phase of PD and the factors involved has been a major hurdle in the study of PD

Environmental triggers of Parkinson’s disease – Implications of the Braak and dual-hit hypotheses Read More »